SC-201

SC-201 is an experimental nanobody-drug conjugate (NDC) currently in preclinical development by Conjustar Biologics for the treatment of solid tumors. As an NDC, it utilizes a single-domain antibody (VHH or nanobody) as the targeting moiety, which is significantly smaller than traditional monoclonal antibodies. This reduced size is intended to facilitate deeper tissue penetration into solid tumors and more rapid systemic clearance, potentially improving the therapeutic index compared to conventional antibody-drug conjugates (ADCs). The nanobody is conjugated to a cytotoxic payload via a linker system. While the specific molecular target and the nature of the payload for SC-201 have not been publicly disclosed by the developer, the asset represents a key part of Conjustar's proprietary nanobody platform aimed at advancing next-generation precision oncology therapeutics.